IL2 and leukemia: The <i>in vivo</i> anti-tumor efficacy was assessed using a metastatic leukemia xenograft mouse model.<h4>Results</h4>NK92-IL-7R-IM cells exhibited sustained proliferation and high viability independent of exogenous cytokines, superior to IL-2-activated NK cells.